Parse Biosciences, the leader in scalable and accessible single cell sequencing, has significantly expanded its global reach through strategic partnerships with two major service providers joining its newly launched Certified Service Provider (CSP) Program. The Seattle-based company welcomed both Tempus and Netherlands-based Single Cell Discoveries to its network, marking a pivotal expansion in making advanced single cell technologies more accessible to researchers worldwide.
Strategic Partnership with Tempus Advances Multi-Omics Research
Tempus has joined Parse's CSP Program to enhance its integrated multi-omics offerings by leveraging Parse's scalable single cell platform. The partnership enables Tempus to combine Parse's proven scalability and quality with its own data-driven expertise, providing customers with a reliable pathway from exploratory research to large, data-driven studies.
"We share Parse's mission to offer reliable and emerging solutions for research, and we look forward to offering our customers single cell sequencing to further this work," said Mike Yasiejko, Executive Vice President at Tempus.
The collaboration addresses the growing demand for comprehensive multi-omics approaches in biomedical research, allowing researchers to conduct more sophisticated analyses that integrate multiple data types for deeper biological insights.
European Expansion Through Single Cell Discoveries Partnership
Single Cell Discoveries has become the first European service provider to join Parse's CSP Program, significantly expanding access to Parse's single cell technology across Europe and worldwide. The Netherlands-based company brings over a decade of expertise, having completed more than 1,000 projects and sequenced millions of single cells across 50+ species.
"Becoming the first service provider in Europe to join Parse's Certified Service Provider program reflects our commitment to leadership in single cell science," said Mauro Muraro, PhD, co-founder and CEO of Single Cell Discoveries. "Partnering with Parse's scalable, fixation-friendly technology allows us to deliver high-quality results at the pace modern research demands, whether for a focused pilot or an atlas-scale study."
Rigorous Standards Drive Program Success
The CSP Program, introduced in 2024, connects researchers with rigorously vetted partners for outsourcing single cell projects of any size. By maintaining exacting standards for data quality, scalability, and service, the program helps laboratories accelerate discovery with confidence while ensuring consistent, high-quality results across different geographic regions.
"We've always been focused on making single cell analysis accessible, scalable, and impactful, and this work with Tempus advances that goal," said Alex Rosenberg, PhD, Co-founder and CEO of Parse Biosciences. "By joining forces, we can deliver the scale and integrated data needed to tackle complex biological questions across the life sciences."
Technology Platform Drives Biomedical Breakthroughs
Parse Biosciences has established itself as a major force in single cell sequencing, having raised over $100 million and serving over 3,000 labs worldwide. The company's expanding product portfolio includes Evercode Whole Transcriptome, Evercode TCR, Evercode BCR, CRISPR Detect, Gene Select, and Trailmaker for advanced data analysis.
Built upon transformative technology developed at the University of Washington, Parse's innovative solutions are driving breakthroughs in cancer treatment, tissue repair, stem cell therapy, and other critical areas of biomedical research. The company recently inaugurated a 34,000-square-foot facility featuring state-of-the-art laboratories in Seattle's South Lake Union district to support its mission of advancing global research.
Impact on Research Accessibility
The expansion of Parse's CSP network ensures researchers have reliable, regional access to best-in-class single cell services, addressing a critical need in the scientific community for scalable, high-quality single cell analysis capabilities. Single Cell Discoveries leverages state-of-the-art laboratory facilities, advanced sequencing platforms, and tailored bioinformatics support, combining high-throughput automation with fast turnaround times and excellence in single-cell preparation.
These partnerships represent a significant step forward in democratizing access to advanced single cell technologies, enabling researchers worldwide to conduct more comprehensive studies and accelerate scientific discovery across multiple disciplines.
